Raymond James Financial Services Advisors Inc. Has $243,000 Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Raymond James Financial Services Advisors Inc. trimmed its position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 5.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,802 shares of the company’s stock after selling 1,775 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Voyager Therapeutics were worth $243,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its holdings in shares of Voyager Therapeutics by 0.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 192,869 shares of the company’s stock valued at $1,495,000 after buying an additional 1,455 shares during the last quarter. Gladius Capital Management LP bought a new position in shares of Voyager Therapeutics during the 3rd quarter valued at $25,000. Silverarc Capital Management LLC lifted its stake in shares of Voyager Therapeutics by 4.0% in the 3rd quarter. Silverarc Capital Management LLC now owns 103,966 shares of the company’s stock valued at $806,000 after purchasing an additional 3,966 shares during the last quarter. Barclays PLC increased its position in Voyager Therapeutics by 188.8% during the third quarter. Barclays PLC now owns 18,309 shares of the company’s stock worth $141,000 after buying an additional 11,970 shares during the last quarter. Finally, Aigen Investment Management LP acquired a new stake in shares of Voyager Therapeutics in the third quarter worth about $109,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on VYGR shares. Wells Fargo & Company upgraded Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $9.00 to $14.00 in a report on Tuesday, January 2nd. Guggenheim started coverage on shares of Voyager Therapeutics in a report on Tuesday, March 26th. They set a “buy” rating and a $22.00 price objective on the stock. StockNews.com upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 9th. HC Wainwright started coverage on Voyager Therapeutics in a research note on Tuesday, March 19th. They set a “buy” rating and a $30.00 price objective for the company. Finally, Citigroup initiated coverage on shares of Voyager Therapeutics in a report on Thursday, March 7th. They issued a “buy” rating and a $16.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Voyager Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $19.33.

Voyager Therapeutics Stock Up 1.1 %

Voyager Therapeutics stock opened at $7.65 on Wednesday. The stock has a 50-day simple moving average of $8.79 and a 200 day simple moving average of $7.97. The stock has a market capitalization of $415.40 million, a price-to-earnings ratio of 2.48 and a beta of 0.96. Voyager Therapeutics, Inc. has a 12-month low of $6.06 and a 12-month high of $14.34.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $1.84. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. The company had revenue of $90.06 million during the quarter, compared to the consensus estimate of $4.95 million. As a group, sell-side analysts anticipate that Voyager Therapeutics, Inc. will post -1.64 EPS for the current year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.